BCL6 and neoplasm: As the deletion of Bcl6 in Treg cells resulted in significantly delayed tumor progression in the 4NQO-induced carcinogenesis model, we hypothesized that Bcl6 may represent a potential therapeutic target in HNSCC treatment.